Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases.

Guan B, Wang H, Cao S, Rao Q, Wang Y, Zhu Y, Shi Q, Yin H, Wang X, Zhou X.

Ann Diagn Pathol. 2011 Aug;15(4):225-32. doi: 10.1016/j.anndiagpath.2010.10.006. Epub 2011 Mar 10.

PMID:
21396871
2.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
3.

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.

Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.

Cancer. 2003 Mar 15;97(6):1573-81.

4.

Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.

Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L.

Breast Cancer Res Treat. 2010 Dec;124(3):677-88. doi: 10.1007/s10549-010-0790-6. Epub 2010 Mar 9.

PMID:
20213083
5.

May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis.

Wang H, Guan B, Shi Q, Ma H, Zhou H, Wang X, Zhou X.

Med Oncol. 2011 Mar;28(1):42-50. doi: 10.1007/s12032-009-9399-1. Epub 2009 Dec 30.

PMID:
20041316
6.

HER-2 amplification in tubular carcinoma of the breast.

Oakley GJ 3rd, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW.

Am J Clin Pathol. 2006 Jul;126(1):55-8.

PMID:
16753605
7.

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.

Prati R, Apple SK, He J, Gornbein JA, Chang HR.

Breast J. 2005 Nov-Dec;11(6):433-9.

PMID:
16297088
8.
9.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005. Epub 2009 Aug 19.

PMID:
19695680
10.

Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

Cancer. 1994 Sep 1;74(5):1575-83.

PMID:
7914825
11.
12.

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL.

J Clin Oncol. 2008 Jul 10;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
18612148
13.

The association of HER-2/neu amplification with breast cancer recurrence.

Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V.

Arch Surg. 2000 Dec;135(12):1469-74.

PMID:
11115354
16.

Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.

Bhargava R, Naeem R, Marconi S, Luszcz J, Garb J, Gasparini R, Otis CN.

Hum Pathol. 2001 Dec;32(12):1344-50.

PMID:
11774167
17.

Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG.

Mod Pathol. 2007 Jan;20(1):84-9. Epub 2006 Nov 24.

18.

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.

Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S, Sakamoto G.

Cancer. 2001 Dec 15;92(12):2965-74.

PMID:
11753973
19.

A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.

Sun JM, Han W, Im SA, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ, Choe KJ, Kim NK.

Cancer. 2004 Dec 1;101(11):2516-22.

20.

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.

Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.

Cancer. 2005 Oct 1;104(7):1391-7.

Supplemental Content

Support Center